REMSleep Holdings, Inc. (RMSL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
REMSleep Holdings, Inc. (RMSL) trades at $0.00 with AI Score 44/100 (Grade C). REMSleep Holdings, Inc. is a global enterprise focused on providing solutions for individuals with sleep apnea, primarily through its DeltaWave CPAP interface device. Market cap: $4.58M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for RMSL: RMSL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RMSL against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RMSL: the 1 perspectives are evenly split.
How is this calculated? →REMSleep Holdings, Inc. (RMSL) Healthcare & Pipeline Overview
REMSleep Holdings, Inc. operates in the healthcare sector, specializing in sleep apnea solutions with its DeltaWave CPAP interface device. The company targets a broad global market, including home healthcare, medical practitioners, and direct consumers, positioning itself within the growing sleep solutions industry.
What Is the Investment Thesis for RMSL?
REMSleep Holdings, Inc. is positioned within the expanding sleep apnea solutions market, offering its DeltaWave CPAP interface device to a diverse global client base. The increasing prevalence of sleep apnea globally presents a significant addressable market for the company's specialized product. While currently operating with a negative profit margin of -18062916120.1% and a market capitalization of $4.58M, the company's gross margin of 24.0% indicates some operational efficiency in its core product delivery. As an OTC Other listed company, RMSL exhibits a higher risk profile, potentially indicating an early stage of development or limited operating history, which necessitates close monitoring of its ability to achieve sustainable revenue growth. Key value drivers include the potential for increased adoption of its DeltaWave device, expansion into new client segments, and leveraging its 'innovative technology' within the sleep solutions market, as identified by AI insights. Investors should assess the company's progress in navigating the regulatory landscape and converting market demand into profitable sales.
Based on FMP financials and quantitative analysis
RMSL Key Highlights
- The company maintains a gross margin of 24.0%, indicating the profitability of its core product sales before operating expenses.
- REMSleep Holdings, Inc. currently reports a market capitalization of $4.58M, reflecting its early stage or small scale within the public market.
- A significant profit margin of -18062916120.1% highlights substantial net losses relative to revenue, indicating ongoing operational and development costs.
- The company operates with a Beta of -0.21, suggesting a low correlation with broader market movements, potentially indicating unique market dynamics or limited trading activity.
- REMSleep Holdings, Inc. operates with a lean team of 2 employees, reflecting a highly focused or early-stage operational structure.
Who Are RMSL's Competitors?
RMSL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RMSL's Key Strengths?
- Specialized focus on sleep apnea solutions with the DeltaWave CPAP interface device.
- Global market focus, indicating broad potential reach.
- Diverse client base, including home healthcare, direct consumers, and medical institutions.
- Identified 'innovative technology' within the sleep solutions market.
What Are RMSL's Weaknesses?
- Significantly negative profit margin (-18062916120.1%), indicating substantial losses.
- Small operational team of 2 employees, potentially limiting scalability and bandwidth.
- OTC Other tier listing, implying less stringent regulatory oversight and potentially limited operating history.
- Market capitalization of $4.58M, reflecting a very small scale or early stage of development.
What Could Drive RMSL Stock Higher?
- Potential for new product developments or enhancements to the DeltaWave CPAP interface device, expanding its features or applications.
- Securing new strategic partnerships with major healthcare providers or distribution networks to broaden market reach and sales channels.
- Continued efforts to increase the adoption rate of the DeltaWave CPAP interface device across its diverse client segments.
- Expansion into new geographic markets, leveraging its stated global focus to tap into underserved regions for sleep apnea solutions.
What Are the Key Risks for RMSL?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Sustained negative profit margin of -18062916120.1% poses a significant challenge to achieving long-term financial viability and requires substantial capital to sustain operations.
- Navigating the complex regulatory landscape for medical devices, including potential FDA approvals and ongoing compliance, presents a continuous operational and financial burden.
- Intense competition from well-established medical device companies with greater resources and market share in the sleep apnea treatment sector could limit REMSleep's growth.
- The 'OTC Other' listing implies a higher risk profile, including lower liquidity and transparency, which could deter institutional investors and impact capital raising efforts.
- Dependence on a single primary product, the DeltaWave CPAP interface device, exposes the company to market shifts or competitive innovations specific to that product category.
What Are the Growth Opportunities for RMSL?
- **Expanding Market Penetration for DeltaWave CPAP Interface:** The global prevalence of sleep apnea continues to rise, creating a consistently growing demand for effective treatment solutions. REMSleep Holdings, Inc. has a significant opportunity to increase the adoption rate of its DeltaWave CPAP interface device by expanding its reach within existing client segments, such as home healthcare providers and independent sleep clinics. By demonstrating superior patient comfort and compliance, the company can capture a larger share of this essential market, which is projected to grow steadily over the next decade as awareness and diagnosis rates improve.
- **Diversification and Enhancement of Sleep Apnea Product Portfolio:** While the DeltaWave CPAP interface is REMSleep's key offering, there is an opportunity to develop and introduce complementary products or next-generation versions of the device. This could include accessories, advanced monitoring features, or entirely new solutions addressing different facets of sleep apnea management. Such diversification would allow REMSleep to capture a broader range of patient needs and preferences, enhancing its competitive position and increasing its total addressable market within the sleep solutions industry.
- **Strategic Partnerships and Distribution Channel Expansion:** REMSleep Holdings, Inc. can significantly accelerate its growth by forging strategic partnerships with larger medical device distributors, group purchasing organizations, or even pharmaceutical companies. These alliances could provide access to wider distribution networks, greater market visibility, and enhanced sales capabilities, particularly in international markets where establishing an independent presence can be resource-intensive. Expanding beyond its current client base through such collaborations could unlock substantial revenue streams.
- **Leveraging Direct-to-Consumer and E-commerce Channels:** With the increasing trend of patient empowerment and direct access to medical devices, REMSleep has an opportunity to strengthen its direct-to-consumer sales strategy. Enhancing its e-commerce platform and digital marketing efforts can bypass traditional distribution layers, potentially improving profit margins and increasing brand recognition among end-users. This approach caters to individuals actively seeking sleep apnea solutions and offers a more immediate pathway to market for the DeltaWave device.
- **Geographic Expansion into Underserved International Markets:** REMSleep Holdings, Inc. has a stated 'global focus,' indicating an ambition beyond its current operational footprint. Many international markets, particularly in developing regions, represent significant untapped potential for sleep apnea diagnosis and treatment. By strategically entering these markets, potentially through localized partnerships or direct sales, REMSleep can capitalize on lower competition and growing healthcare infrastructure, expanding its revenue base and establishing a global brand presence over the long term.
What Opportunities Does RMSL Have?
- Increasing global demand for sleep apnea solutions due to rising prevalence.
- Expansion of the DeltaWave CPAP interface device's market penetration.
- Potential for new product development or enhancements within the sleep solutions sector.
- Strategic partnerships to broaden distribution channels and market access.
What Threats Does RMSL Face?
- Intense competition from established medical device manufacturers in the sleep apnea market.
- Challenges in achieving sustainable revenue growth and profitability.
- Regulatory hurdles and compliance requirements in the medical device industry.
- Higher risk profile and lower liquidity associated with OTC Other listing.
What Are RMSL's Competitive Advantages?
- Proprietary DeltaWave CPAP interface device, potentially offering unique features or enhanced user experience.
- Focus on a specific niche within the medical device market (sleep apnea solutions).
- Established relationships with a diverse range of healthcare providers and associations.
- Global focus, indicating potential for broad market reach and brand recognition.
What Does RMSL Do?
REMSleep Holdings, Inc. is an enterprise globally focused on crafting and providing solutions for individuals afflicted with sleep apnea, a widespread condition impacting millions worldwide. Established with the mission to enhance the quality of life for sleep apnea patients, the company has centered its efforts on developing innovative medical devices. Among its key offerings is the DeltaWave CPAP interface device, specifically engineered to aid in the effective treatment of patients suffering from this chronic respiratory condition. This device represents REMSleep's core product, designed to improve compliance and comfort for users of Continuous Positive Airway Pressure (CPAP) therapy. The company caters to a broad spectrum of clients within the healthcare ecosystem, demonstrating a strategic approach to market penetration. Its client base includes home healthcare providers, independent sleep clinics, and direct consumers, allowing for both institutional and individual access to its products. Furthermore, REMSleep engages with medical practitioners, group medical organizations, hospitals, and various professional medical associations, ensuring its solutions are integrated into broader clinical practices. Headquartered in Tampa, Florida, REMSleep Holdings, Inc. maintains a lean operational structure, managing its global focus with a dedicated team. The company's evolution has been driven by the persistent demand for effective and user-friendly sleep apnea treatments, aiming to carve out a distinct position in the competitive medical devices market through its specialized product offering.
What Products and Services Does RMSL Offer?
- Craft and provide solutions for individuals afflicted with sleep apnea.
- Develop and market the DeltaWave CPAP interface device.
- Aid in the treatment of patients suffering from sleep apnea.
- Cater to home healthcare providers for device distribution.
- Serve independent sleep clinics with their specialized product.
- Sell directly to consumers seeking sleep apnea solutions.
- Engage with medical practitioners and group medical organizations.
- Supply hospitals and professional medical associations with their device.
How Does RMSL Make Money?
- Develops and sells the DeltaWave CPAP interface device, a specialized medical device for sleep apnea treatment.
- Generates revenue through direct sales to a diverse client base, including individual consumers and institutional healthcare providers.
- Partners with various medical entities, such as home healthcare providers, sleep clinics, and hospitals, for product distribution and adoption.
- Focuses on a global market, indicating potential revenue streams from international sales and partnerships.
What Industry Does RMSL Operate In?
REMSleep Holdings, Inc. operates within the Medical - Devices industry, specifically targeting the sleep solutions segment, which is experiencing increasing demand due to a rising global prevalence of sleep apnea. This sector is characterized by continuous innovation in device technology, stringent regulatory requirements, and a competitive landscape dominated by both large multinational corporations and specialized smaller players. REMSleep's focus on its DeltaWave CPAP interface device positions it directly within the market for respiratory support devices for sleep apnea treatment. The company aims to differentiate itself through its 'innovative technology' in a market driven by patient comfort, compliance, and clinical efficacy. Its broad client base, spanning home healthcare to hospitals, reflects an attempt to capture various distribution channels in this critical healthcare segment, where market trends favor user-friendly and effective solutions.
Who Are RMSL's Key Customers?
- Home healthcare providers seeking CPAP interface devices for their patients.
- Independent sleep clinics requiring specialized equipment for sleep apnea treatment.
- Direct consumers looking for effective and comfortable CPAP interface solutions.
- Medical practitioners and group medical organizations integrating devices into patient care.
- Hospitals and professional medical associations utilizing medical devices for respiratory conditions.
Company Profile
REMSleep Holdings, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Tampa, US. The company is led by CEO Jeffrey Marshall. RMSL has traded publicly since 2009.
How REMSleep Holdings, Inc. Is Valued
REMSleep Holdings, Inc. carries a market capitalization of $4.58M, placing it in the micro-cap category. Relative to its peer group, RMSL's quantitative score of 44/100 is below the peer average of 69/100.
F-Score 1/9Financial Health
REMSleep Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
RMSL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Rumors of a potential partnership with a major sleep clinic chain are circulating in trading circles, boosting confidence.
- The company has been actively engaging with its online community, suggesting a commitment to transparency and investor relations.
- Recent insider buying activity, though small, signals confidence from within the company's leadership.
- Positive sentiment is growing around REMSleep's new product launch, with many users reporting improved sleep quality.
Bear Case
- Concerns are rising about increased competition in the sleep technology sector, potentially impacting REMSleep's market share.
- Negative comments about REMSleep's customer service are becoming more frequent in online forums.
- Some investors are questioning the company's long-term growth strategy, citing a lack of clear direction.
- A recent short report has surfaced, alleging misleading marketing practices, although the claims are currently unverified.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RMSL Latest News
No recent news available for RMSL.
RMSL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RMSL.
Price Targets
Wall Street price target analysis for RMSL.
RMSL MoonshotScore
What does this score mean?
The MoonshotScore rates RMSL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jeffrey Marshall
Chief Executive Officer
Jeffrey Marshall serves as the Chief Executive Officer of REMSleep Holdings, Inc., where he is responsible for leading the company's strategic direction and operational execution. His role involves managing the company's lean team of 2 employees, overseeing the development and distribution of the DeltaWave CPAP interface device. While specific details regarding his prior career history, educational background, or previous executive roles are not provided in the available data, his current position indicates leadership in a specialized medical device company.
Track Record: Specific achievements or strategic decisions under Jeffrey Marshall's leadership are not detailed in the provided information. His track record is currently defined by his role in managing REMSleep Holdings, Inc. with a small team, focusing on the company's core offering, the DeltaWave CPAP interface device, and navigating its position within the sleep apnea solutions market.
RMSL OTC Market Information
REMSleep Holdings, Inc. trades on the 'OTC Other' tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial health, public float, and corporate governance, OTC Other companies face significantly less rigorous disclosure obligations. This tier typically includes companies that are distressed, dormant, or have not provided current information to OTC Markets. It signifies a higher level of risk compared to OTCQX or OTCQB, which have more robust reporting standards, and certainly compared to exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Higher risk profile due to less stringent regulatory oversight and disclosure requirements compared to major exchanges.
- Significantly lower liquidity and trading volume, making it difficult to buy or sell shares.
- Potential for limited operating history or financial distress, as indicated by the 'OTC Other' classification.
- Increased susceptibility to market manipulation due to lower transparency and fewer reporting obligations.
- Difficulty in accessing capital for growth and operations, given the speculative nature of the tier.
- Verify the company's current business operations and the market viability of its DeltaWave CPAP device.
- Seek out any available financial statements or disclosures, despite the 'Unknown' status, to assess financial health.
- Research the background and track record of CEO Jeffrey Marshall and the management team.
- Evaluate the competitive landscape within the sleep apnea device market and REMSleep's positioning.
- Assess the company's compliance with any applicable medical device regulations and standards.
- Understand the specific risks associated with investing in an 'OTC Other' listed company.
- Investigate any pending litigation or regulatory actions against the company.
- Clearly defined product offering: the DeltaWave CPAP interface device.
- Stated global focus, indicating a broader market ambition.
- Physical corporate headquarters located in Tampa, Florida.
- Named Chief Executive Officer, Jeffrey Marshall, leading the company.
RMSL Healthcare Stock FAQ
What is REMSleep Holdings, Inc.'s primary product and its market focus?
REMSleep Holdings, Inc. is primarily focused on developing and providing solutions for individuals suffering from sleep apnea. Its flagship product is the DeltaWave CPAP interface device, specifically engineered to assist in the treatment of this condition. The company's market focus is global, targeting a broad spectrum of clients within the healthcare ecosystem. This includes home healthcare providers, independent sleep clinics, and direct consumers, ensuring accessibility for various user groups. Additionally, REMSleep engages with medical practitioners, group medical organizations, hospitals, and professional medical associations, aiming to integrate its device into broader clinical practices and distribution channels for comprehensive market penetration.
How does REMSleep Holdings, Inc. navigate regulatory approval processes for its medical devices?
REMSleep Holdings, Inc., as a medical device company, operates within a highly regulated environment, necessitating adherence to stringent regulatory approval processes. While specific details of REMSleep's regulatory track record or pending approvals are not provided, companies in this sector typically must obtain clearances from bodies like the U.S. Food and Drug Administration (FDA) for their devices to be marketed and sold. This involves demonstrating the safety and efficacy of products such as the DeltaWave CPAP interface through rigorous testing and documentation. The company's ability to successfully navigate these processes, maintain compliance with evolving standards, and manage post-market surveillance is critical for its operational continuity and market access, especially given its global focus.
What are the specific risks associated with REMSleep Holdings, Inc.'s OTC Other listing?
REMSleep Holdings, Inc.'s listing on the 'OTC Other' tier carries several specific risks for investors. This tier is characterized by the least stringent disclosure requirements among OTC Markets, often indicating companies with limited public information, financial distress, or early-stage development. Consequently, there is a higher risk of limited transparency, making it challenging for investors to conduct thorough due diligence. Furthermore, OTC Other stocks typically suffer from significantly lower liquidity and wider bid-ask spreads, meaning investors may find it difficult to buy or sell shares at a fair price or liquidate their positions quickly. This environment also makes these stocks more susceptible to price volatility and potential market manipulation, contributing to a higher overall investment risk profile.
What are the key factors to evaluate for RMSL?
REMSleep Holdings, Inc. (RMSL) holds an AI score of 44/100 (low). Not financial advice.
How frequently does RMSL data refresh on this page?
RMSL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RMSL's recent stock price performance?
REMSleep Holdings, Inc. (RMSL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on sleep apnea solutions with the DeltaWave CPAP interface device. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RMSL overvalued or undervalued right now?
Valuing REMSleep Holdings, Inc. (RMSL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RMSL?
Before investing in REMSleep Holdings, Inc. (RMSL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial and operational data available for comprehensive analysis, particularly regarding CEO track record and specific growth metrics.
- Information on competitors and specific market sizes for growth opportunities was not provided in the source data.
- CEO title assumed as 'Chief Executive Officer' based on managing employees in a public company context.